HUTCHMED (China) Limited has announced that new and updated data from several studies of its compounds will be presented at upcoming international conferences. The data, focusing on the treatment of non-small cell lung cancer (NSCLC), will be showcased at the 2025 World Conference on Lung Cancer in Barcelona, Spain, and the Chinese Society of Clinical Oncology Annual Meeting 2025 in Jinan, China. Among the studies to be presented are updated analyses from the SACHI, SAVANNAH, and a Phase IIIb confirmatory study involving the MET tyrosine kinase inhibitor, savolitinib. This drug is being jointly developed and commercialized by AstraZeneca and HUTCHMED.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief on September 05, 2025, and is solely responsible for the information contained therein.